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Nephronophthisis is an autosomal recessive chronic
tubulointerstitial disease that progresses to end-stage renal
disease (ESRD) in about 10% of cases during infancy.
Mutations in the INVS (NPHP2) gene were found in a few
patients with infantile nephronophthisis. Mutations of
NPHP3, known to be associated with adolescent
nephronophthisis, were found in two patients with early-
onset ESRD. Here we screened 43 families with infantile
nephronophthisis (ESRD at less than 5 years of age) for
NPHP2 and NPHP3 mutations and determined
genotype–phenotype correlations. In this cohort there were
16 families with NPHP2 mutations and 7 with NPHP3
mutations. Three patients carried only one heterozygous
mutation in NPHP3. ESRD arose during the first 2 years of life
in 16 of 18 patients with mutations in NPHP2 but in only two
patients with mutations in NPHP3. Renal morphology,
characterized by hyper-echogenic kidneys on ultrasound and
tubular lesions with interstitial fibrosis on histology, was
similar in the two patient groups. The kidney sizes were
highly diverse and ultrasound-visualized cysts were present
in a minority of cases. Extra-renal anomalies were found in
80% of the entire cohort, including hepatic involvement
(50%), cardiac valve or septal defects (20%) and recurrent
bronchial infections (18%). We show that NPHP3 mutations in
both infantile and adolescent nephronophthisis point to a
common pathophysiological mechanism despite their
different clinical presentations.
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Nephronophthisis (NPH) is an autosomal recessive chronic
tubulointerstitial nephropathy, which in all cases progresses
to end-stage renal disease (ESRD). Three clinical variants
have been described according to the age at onset of ESRD:
infantile, juvenile, and adolescent. Juvenile NPH is the most
common, and it accounts for 5–10% of cases of ESRD in
children. The kidneys in juvenile and adolescent NPH are of
normal or even reduced size, and are characterized
histologically by interstitial fibrosis and tubular atrophy with
basement membrane splitting and thickening. Cysts develop
late in the course of the disease, typically at the corticome-
dullary junction.1,2
A clinically distinct disorder was later recognized and
characterized by autosomal recessive inheritance and rapidly
progressive, chronic tubulointerstitial nephritis leading to
ESRD before the age of 3 years.3–5 This condition was
considered to be the infantile form of NPH because of the
presence of interstitial fibrosis. However, the enlargement of
the kidneys with cortical cysts, the lack of basement
membrane thickening, and the frequent association with
hepatic fibrosis were more reminiscent of polycystic kidney
disease than of NPH.
Mutations in seven genes, NPHP1 and NPHP3 to NPHP8,
have been found in juvenile or adolescent NPH.6–16 NPHP2
(INVS) was the only gene implicated in the infantile form17
until recently, when two patients with early-onset ESRD were
found to carry NPHP3 mutations.18,19 Here we present a
comprehensive study of a cohort of 43 families to assess the
prevalence of mutations of NPHP2 and NPHP3 in cases of
infantile NPH. We analyzed the genotype–phenotype correlation
with respect to the clinical and pathological presentation.
RESULTS
NPHP2 mutations
Thirteen different NPHP2 mutations were identified in 16
unrelated families (Table 1, Figure 1a). Five mutations were
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novel, three of which were truncating mutations (p.Q671X,
p.W188X, p.K916fsX1002), one affected an obligatory
splice site (c.615þ 1G4A), and one was a missense mutation
(p.C398W). The amino-acid substitution (p.C398W)
resulting from the missense mutation was considered to be
pathogenic because the affected cysteine, located in the
ankyrin domain (Figure 1a), is conserved in vertebrates,
and a tryptophan was not found in this position in any
of 166 ethnically matched controls. This substitution
was also predicted to be damaging by the PolyPhen program
(PSIC score: 3.15). One patient was heterozygous for the
variant p.A650P (F75-1, Supplementary Table 1):
although this variant was previously considered to be
a missense mutation,19 we found it in 6/152 ethnically
matched controls, and therefore we considered it to be a
polymorphism.
Our study and earlier work by others17,18 have thus
revealed five NPHP2 mutations that are recurrent in
unrelated families (p.R899X, p.R907X, p.Q485fsX509,
p.Q671X, and p.E970fsX971) (Table 1).
Table 1 | Genetic and clinical characteristics of patients with NPHP2 mutations
Ind CS Origin
Nucleotide
seq (exon,
segregation)
Alterations in
coding seq
Diagnosis
(months)
Symptoms
at dg
ESRD
(months)
Renal
ultrasound
Renal
histology HT Liver
Other extra-renal
symptoms
A12-1a + Israel c.2719C4T H
(14)
p.R907X 5 ND 5 ND Infantile type + — —
F339-1 + Israel c.2719C4T H
(14)
p.R907X ND Anemia,
PU–PD, FT
32 ND Infantile type ND — —
F339-2 Not sequenced ND ND ND 19 ND ND ND ND ND
1499 + Israel c.2719C4T H
(14, P, M)
p.R907X 9 ND 16 SK, HE, cyst End-stage K + — Developmental delay
F331-1 + Morocco c.2011C4T H
(13)
p.Q671X 11 Anemia,
PU–PD, FT
11 NSK, HE,
no cyst
Infantile type + — Hypertriglyceridemia
(6.6 mmol/l), bilateral hip
dysplasia
A8-1a + Turkey c.1807C4T H
(13)
p.R603X 12 Anemia 18 EK, HE, no cyst Infantile type + ET Situs inversus, ventricular
septal defect, recurrent
bronchitis
1383  France c.1453delC h
(10, P)
c.2695C4T h
(14, M)
p.Q485fsX509
p.R899X
18 Anemia,
PU–PD, FT
18 NSK (1SD),
HE, no cyst
ND + — —
F411-1  France c.1453delC h
(10, P)
c.2908delG h
(15, M)
p.Q485fsX509
p.E970fsX971
36 Anemia,
FT
36 SK (2,5SD),
HE, no cyst
Juvenile type + — Cerebellar atrophy without
vermis aplasia, mitral
insufficiency
A6-1a  France c.1453delC h
(10, M)
c.2695C4T h
(14, P)
p.Q485fsX509
p.R899X
21 Anemia,
FT
21 NSK (1SD),
HE, no cyst
Juvenile type + — Recurrent bronchitis and
upper respiratory infections,
onycholysis
A7-1a  Portugal c.1478T4C H
(11)
p.L493S 5 Anemia,
FT
18 EK (+2SD), HE,
cysts
Infantile type + — Perception deafness
F413-1  France c.1453delC h
(10, P)
c.2695C4T h
(14, M)
p.Q485fsX509
p.R899X
9 PU–PD, FT 9 NSK, HE, cysts Infantile type + HF —
A9-1a  France c.1186C4T h (9,
M)
c.1445C4G h
(10, P)
p.R396X p.P482R 11 Anemia,
PU–PD, FT
20 EK, HE, cysts Juvenile type + — Mitral insufficiency
A9-2a Not sequenced 5 Anemia,
PU–PD
20 EK (+2SD),
HE, cysts
ND + — Supravalvular pulmonary
stenosis, patent foramen ovale
F320-1 + France c.2719C4T H
(14)
p.R907X 12 Anemia,
FT
13 SK (2,5SD),
HE, no cyst
Infantile type + — Developmental delay,
recurrent bronchitis and otitis
F398-1  France c.615+1G4A h
(5, P)
c.2011C4T h
(13, M)
Abn transcript
p.Q671X
5 FT 10 NSK, no cyst Infantile type ND HF —
F434-1  France c.1194T4G h
(9)
c.2695C4T h
(14)
p.C398W
p.R899X
18 Anemia,
FT
18 EK, HE, no cyst Infantile type + HF Situs inversus, aortic and
pulmonary valve stenosis,
recurrent bronchitis
F340-1  France c.563G4A h (5,
M)
c. 2747insA h
(14, P)
p.W188X
p.K916fsX1002
5 ND 12 EK, HE, no cyst Infantile type + — —
A10-1a  France c.2908delG h
(15, M)
p.E970fsX971 12 Anemia,
PU–PD
12 EK, HE, no cyst ND + — —
Abn, abnormal; CS, consanguineous; EK, enlarged kidney; ET, elevated serum transaminase level; FT, failure to thrive; h, heterozygous; H, homozygous; HE, hyperechogenic
kidney; HF, hepatic fibrosis; HT, hypertension; Ind, individual; K, kidney; ND, no data available; NSK, normal-sized kidney; PU–PD, polyuria–polydipsia; SD, standard deviation;
SK, small kidney.
aFamilies already published.17
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In our cohort, seven families were homozygous for either a
truncating (n¼ 6) or a missense1 mutation and eight families
were compound heterozygous for two truncating mutations,5
one truncating and one missense mutation,2 or one
truncating and one splice site mutation1 (Table 1). In family
A10, only one heterozygous truncating mutation was
identified.
Phenotype of patients with NPHP2 mutations
In the 16 families with NPHP2 mutations, 18 children were
affected (Table 1). The median age of the patients at diagnosis
was 11 months (range: 5–36 months). Renal function
deteriorated rapidly; ESRD was already present in half of
the patients at the time of diagnosis and developed in all but
two patients before the age of 2 years (median age: 18 months
(range: 5–36 months), Table 1). Hypertension was a
consistent finding. Ultrasound investigations revealed hyper-
echogenic kidneys in all but one case. In contrast, kidney size
was variable: kidneys were enlarged in seven, normal-sized in
five, and small in three cases. Cysts were detected in five of 15
patients.
Severe tubulointerstitial lesions were present in the 12
renal biopsies and in the five nephrectomy specimens
studied. In nine biopsies (patients A12-1, F339-1, F331-1,
A8-1, A7-1, F320-1, F398-1, F434-1, F340-1, Table 1), the
histological pattern was typical of infantile NPH. In these
cases, cortical tubules showed focal cystic dilatation and were
lined by small cuboidal epithelial cells, or alternatively
appeared collapsed and lined by a flat dedifferentiated
epithelium (Figure 2a). Furthermore, diffuse moderate
interstitial fibrosis was a constant feature in these patients,
associated with mild focal cellular infiltration. Glomeruli
were normal, sclerotic, or ischemic with a retracted capillary
tuft surrounded by a thickened Bowman’s capsule. Impor-
tantly, thickened tubular basement membranes were rare. In
contrast, the lesions observed in two of the 12 biopsies (F411-
1, A6-1) were similar to those in juvenile NPH with severe
and nearly diffuse atrophy of tubules surrounded by a thick
and irregularly laminated basement membrane (Figure 2b).
In the remaining biopsy (1499), the lesions were advanced
and too severe for precise classification. All five nephrectomy
specimens (A8-1, A7-1, F413-1, A9-1, F320-1) displayed
advanced chronic tubulointerstitial nephropathy with
marked corticomedullary atrophy. A few medullary cysts
were found in three of them (A7-1, F413-1, A9-1), and
cortical microcysts in two (A8-1, F413-1). Marked medial
hypertrophy of the arteries was present in all cases.
Extra-renal manifestations were found in 12 of 17 patients
with available clinical information (Table 1). Heart valve or
septal defects (n¼ 5), hepatic involvement (n¼ 4), and
recurrent bronchial infections (n¼ 4) were the most frequent
findings. Developmental delay (n¼ 2) and situs inversus
(n¼ 2) were also found. In the latter two cases, situs inversus
was associated with heart valve or septal defects.
NPHP3
Inversin
112 kDa, 1065 aa
W188X R396X
C398W
P482R
Q485fsX509
L493S
R603X
615+1G>A
Q671X R899X
R907X
N917fsX943 E970fsX971
C
1716
TGA
15141312111098765432
ATG
1
N
NPHP2/INVS
ATG
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
TGA
TPR
TTL
c.1276-2 A>GE145fsX148
CCN
Nephrocystin-3
146 kDa, 1330 aa
Q855X
C
L1138fsX1139
R1165Q
c.3571-1G>C
R1259X
c.3810_3812+2del5
c.3812+3insT
Figure 1 | Schematic diagram of the localization of the detected NPHP2 and NPHP3 mutations with respect to the exons and to
the functional protein domains. (a) Inversin, the product of the NPHP2/INVS gene, contains 16 tandem ankyrin repeats (gray boxes), two
IQ calmodulin-binding domains (hatched boxes), and two destruction box regions (black bars). (b) Nephrocystin-3, the product of the
NPHP3 gene, contains a coiled-coil domain (CC), a tubulin tyrosine ligase domain (TTL), and a tetratricopeptide-repeat domain (TPR). Most of
the mutations map within the TPR domain.
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NPHP3 mutations
We identified nine different NPHP3 mutations in seven
unrelated patients (Table 2, Figure 1b). Six mutations were
novel: two were nonsense or frameshift mutations (p.Q855X,
p.L1138fsX1139), three were splice site mutations (c.1276-2
A4G, c.3810_3812þ 2del5, c.3812þ 3insT), and one was a
missense mutation (p.R1165Q). All three splice site muta-
tions completely abolished the identification of the junction
sequence by the NetGene2 program. Neither the consensus
splice site mutation (c.3812þ 3insT) nor the other splice site
mutation that affects the donor site of exon 26
(c.3810_3812þ 2del5) was found in 100 ethnically matched
controls. The amino-acid substitution p.R1165Q was pre-
dicted to be benign by PolyPhen (PSIC score: 1.36). This
mutation is likely to be pathogenic because the substituted
arginine, located in the tetratricopeptide domain of nephro-
cystin-3 (Figure 1b), is conserved throughout vertebrate
evolution and was not changed to glutamine in any of 107
ethnically matched control subjects.
Four of the seven patients were either compound
heterozygous for a truncating and a consensus splice site
mutation (n¼ 3) or homozygous for a consensus splice site
mutation (n¼ 1) (Table 2). One of these patients (A11-1)
carries a heterozygous NPHP4 truncating mutation and was
published earlier.19 In three of the seven patients, we
identified only one heterozygous NPHP3 mutation (Table 2):
one affected an obligatory splice site, one was truncating, and
one was the missense mutation p.R1165Q.
Phenotype of patients with NPHP3 mutations
The renal function of the seven unrelated patients with
NPHP3 mutations deteriorated less rapidly than did that of
patients with NPHP2 mutations: they were diagnosed with
renal involvement at the median age of 30 months (range:
2–48) (Tables 2 and 3) and developed ESRD at the median
age of 36 months (range: 6–52). Nevertheless, similar to
patients with NPHP2 mutations, all but one of the patients
with NPHP3 mutations were hypertensive. Renal ultrasound
revealed hyperechogenic kidneys in all patients, and the
kidneys were large in two patients, normal-sized in four, and
small in one patient. Cysts were found by ultrasound in only
two patients.
Diffuse tubulointerstitial lesions were present in all six
renal biopsies studied. In two patients (1348, F271-1; Table 2),
some cortical tubules showed cystic dilatation, and others
were undifferentiated or atrophic, giving a histological
picture consistent with that of infantile NPH (Figure 2a).
Two other patients (F367-1, F369-1) showed thickening and
splitting of the basement membrane, characteristic of juvenile
NPH (Figure 2b). One patient showed severe lesions that
precluded precise classification (patient 1364). Finally, the
major abnormalities in one patient (F440-1) were glomer-
ulocystic lesions that were also noted in the patient’s
nephrectomy specimen. The other available nephrectomy
specimen (F271-1) showed severe corticomedullary atrophy
without medullary cysts. Marked thickening of the arterial
walls was observed in all cases.
All patients showed extra-renal manifestations, with
hepatic involvement affecting all but one patient. Liver
biopsies, when available, showed hepatic fibrosis (Table 2).
The liver biopsy from patient 1348 showed massive portal
Figure 2 | Both ‘juvenile’ and ‘infantile’ type histological
features were found in patients with infantile NPH. (a) Renal
cortex characteristic of the infantile-type NPH. Irregular
microcystic dilatation of cortical tubules. Absence of significant
tubular basement membrane thickening. Interstitial fibro-edema.
Normal glomeruli (light microscopy, periodic acid-Schiff (PAS)
stain,  250). (b) Renal cortex characteristic of the juvenile type.
Most of the tubular basement membranes are thickened and
laminated. Tubules are surrounded by a marked interstitial fibrosis
with focal and moderate cell infiltration (light microscopy, PAS
stain,  280) (c). Microcystic dilatations of cortical tubules in a
patient without NPHP2/NPHP3 mutations (F299-1). Most adjacent
tubules are dedifferentiated; few are surrounded by a thickened
basement membrane (light microscopy, PAS stain,  280).
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fibrosis with fibrous extensions bridging adjacent portal
areas. No true bile duct proliferation was observed, but neo
bile canaliculi were present within the fibrous areas.
Other recurrent extra-renal manifestations in patients
with NPHP3 mutations were cone-shaped epiphyses (n¼ 2)
and heart valve or septal defects (n¼ 2). One patient suffered
recurrent bronchial infections and retinitis pigmentosa.
Phenotype of patients without NPHP2/NPHP3 mutations
No NPHP2 or NPHP3 mutations were found in 22 patients
from 20 families. The ages at diagnosis of renal involvement
(median: 27 months (range: 0–58)) and onset of ESRD
(median: 47 months (range: 9–60)) were variable (Supple-
mentary Table 1). Nevertheless, only two patients developed
ESRD before 2 years of age. Most of the patients were
hypertensive. On ultrasound, hyperechogenicity of the
kidneys was a frequent finding, but cysts were found in only
5 of 14 patients. Similar to patients with identified mutations,
kidney sizes were diverse: enlarged in 1 patient, normal-sized
in 10, and small in 3 patients (Table S1).
Renal histology was studied in 11 patients by analysis of
nine biopsies and five nephrectomy specimens. Juvenile- and
infantile-type histological findings were found in four and
three renal biopsies, respectively (Table S1, Figure 2c). In the
two remaining biopsies, either focal nonspecific tubulointer-
stitial lesions (P1521) or arterial/arteriolar lesions (P1558)
were prominent. Severe corticomedullary atrophy was
present in the five end-stage kidneys. Cortical cysts were
present in four of them (F348-1, F348-2, F350-1, F249-1) and
associated with medullary cysts in one (F249-1); no cystic
lesions were observed in patient F237-1.
Hepatic involvement (n¼ 10), retinitis pigmentosa
(n¼ 6), cone-shaped epiphyses (n¼ 5), and lower respiratory
diseases (n¼ 5) were the most frequent extra-renal involve-
ments in patients with relevant clinical information (Table
S1). Heart valve or septal defects were found in two patients
and situs inversus in another patient. The other extra-renal
anomalies were diverse. Some, including craniosynostosis
and thoracic dystrophy, were not observed in any patient
with NPHP2 or NPHP3 mutations.
DISCUSSION
Infantile NPH was described two decades ago. On the basis of
the different macro- and microscopic renal morphology and
the different genes mutated, infantile NPH and juvenile NPH
Table 2 | Genetic and clinical characteristics of patients with NPHP3 mutations
Ind CS Origin
Nucleotide
seq (exon,
segregation)
Alterations in
coding seq
Diagnosis
(months)
Symptoms
at dg
ESRD
(months)
Renal
ultrasound
Renal
histology HT Liver
Other extra-
renal
symptoms
1348 + Algeria c.1276-2A4G H
(8, P, M)
Abn transcript 2 Anemia,
PU–PD, FT
6 NSK (+1SD),
HE, no cyst
Infantile type  HF Ventricular
septal defect
F369-1  Norway c.2563C4T h (18)
c.3812+3insT h (26)
p.Q855X abn
transcript
30 ND 36 NSK, no cyst Juvenile type ND ET Recurrent
subdural
collections
A11-1a  France c.435_438del4 h
(2, M)
c.3571-1G4C h
(25, P)
p.E145fsX148 abn
transcript
36 PU–PD, FT 37 NSK, cyst ND + HF Recurrent
pneumonias
and bronchitis
F367-1  France c.3412_3413delTT h
(24)
c.3775C4T h (26)
p.L1138fsX1139
p.R1259X
48 Anemia,
PU–PD, FT
52 EK, no cyst Juvenile type + — Mitral
insufficiency,
keratitis
F271-1  France c.3810_3812+2del5 h
(26)
Abn transcript 20 FT 24 SK, HE,
no cyst
Infantile type + HF Cone-shaped
epiphyses,
retinitis
pigmentosa
F440-1  France c.3412_3413delTT h
(24)
p.L1138fsX1139 5 PU–PD, FT 12 EK, HE,
cortical cysts
Glomerulocystic + HF Hypercholes-
terolemia
1364  Algeria c.3494G4A h (24) p.R1165Q 39 Anemia,
PU–PD
39 NSK, HE,
no cyst
End-stage K + ET
EG
Cone-shaped
epiphyses
Abn, abnormal; CS, consanguineous; EG, elevated serum GGT level; EK, enlarged kidney; ET, elevated serum transaminase level; FT, failure to thrive; h, heterozygous; H,
homozygous; HE, hyperechogenic kidney; HF, hepatic fibrosis; HT, hypertension; Ind, individual; K, kidney; ND, no data available; NSK, normal-sized kidney; PU–PD,
polyuria–polydipsia; SD, standard deviation; SK, small kidney.
aFamily already published and known also to carry a heterozygous NPHP4 mutation (c.3364-3367delACTG h).19
Table 3 | Summary of the phenotypes associated with NPHP2
and NPHP3 mutations
NPHP2 mutations
(n=18a)
NPHP3 mutations
(n=7a)
Age at onset of ESRD (median
(range))
18 (5–36) 36 (6–52)
Hypertension 15/15 5/6
Size of the kidney (small/
normal/large)
3/5/7 1/4/2
Hyperechogenic kidneys on
ultrasound
14/15 7/7
Renal cyst on ultrasound 5/15 2/7
Histology
Juvenile typeb 3/14 2/6
Infantile typeb 10/14 2/6
Glomerular cysts 0/14 1/6
Hepatic involvement 4/17 6/7
aThe number of patients with known phenotype is indicated in each line.
bFor the precise description of juvenile-type and infantile-type histological findings,
see the text.
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were considered to be distinct pathological entities. We found
here that patients with infantile NPH may also present with a
renal histology characteristic of juvenile NPH. Until recently,
NPHP2 was the only causative gene identified. We show in
this study that NPHP3 mutations are also associated with
infantile NPH and that these two genes are mutated in half of
the cases in a large cohort of patients with early-onset ESRD.
The onset of ESRD occurs earlier in patients harboring
NPHP2 mutations than in those with NPHP3 mutations, and
NPHP3 mutations are generally associated with liver
abnormalities.
High NPHP2 mutation rate in patients with ESRD before
2 years of age
The NPHP2 mutation rate in our cohort of families with
infantile NPH was high (37%, 16/43), and was 78% (14/18)
in the subgroup of patients developing ESRD before the age
of 2 years. This high prevalence of mutation was unexpected
in view of the findings of Otto et al.,18 who reported NPHP2
mutations in only 2 of 25 NPH patients with early-onset
ESRD (o5 years). However, we found few NPHP2 mutations
in patients with an onset of ESRD between 2 and 5 years of
age; therefore, a different age distribution in the two cohorts
may explain the difference in the observed prevalence of
mutations.
The variant p.A650P was described earlier in the
heterozygous state in a patient with juvenile NPH, who also
carried an NPHP3 heterozygous missense mutation,19 and in
a sibling pair with adolescent NPH and ulcerative colitis.19,20
However, the alanine affected by this mutation is not
conserved and we found a proline at this position in 4% of
the controls. Thus, it is unlikely that this variant is
pathogenic.
Thus, NPHP2 can be considered to be the major causative
gene of infantile NPH, especially in patients developing
ESRD during the first 2 years of life. Its role in juvenile and
adolescent NPH has not been determined.
Different types of NPHP3 mutations in infantile and adoles-
cent NPH
NPHP3 was initially localized by means of linkage analysis in
a large Venezuelan kindred in which ESRD developed at a
median age of 19 years.2 The NPHP3 gene was thus
considered to be responsible for an adolescent form of
NPH. Subsequently, NPHP3 mutations were found in
patients with an onset of ESRD between 7 and 37 years of
age,10 showing that they can also cause juvenile NPH. More
recently, NPHP3 mutations were found in two patients with
an onset of ESRD at 3 and 4 years of age.18,19 Given these new
data, we sought to assess the involvement of NPHP3 in
patients with infantile NPH. Surprisingly, we found a high
prevalence of NPHP3 mutations (7/43 families, 16%).
However, in three of the seven families we found only one
heterozygous mutation, raising the possibility that mutations
in other genes also contribute to the disease phenotype.19,21
Alternatively, a second NPHP3 mutation could have gone
undetected if it had involved a deletion or was located within
an intron or promoter region.
In total, the age at the onset of ESRD linked to mutations
of NPHP3 was highly variable, ranging from infancy to
adolescence. There are two possible explanations for this
variability.
The epistatic effect of a second locus could account for
this variability, as one patient with infantile NPH and two
NPHP3 mutations (A11-1) is also known to carry a
heterozygous NPHP4 frameshift mutation.19 Alternatively,
the variability in the age at the onset of ESRD could be
explained by the different types of NPHP3 mutations found
in patients with infantile and adolescent NPH. In the original
description of adolescent NPH, eight of nine families carried
a hypomorphic mutation on at least one allele;10 in our study,
six of seven families with infantile NPH carried truncating or
consensus splice site mutations. Although we found only one
heterozygous mutation in two of these families, the putative
genotype–phenotype correlation is also supported by the
recent finding that four families with a Meckel-like syndrome
and cystic kidney dysplasia carry truncating or splice site
NPHP3 mutations on both alleles in all but one case.22 A
similar genotype–phenotype correlation was shown in mice
with Nphp3 mutations.22 Thus, missense mutations in
NPHP3 seem to be associated with a late-onset, adolescent
NPH, whereas truncating and splice site mutations are
associated with a more severe phenotype, which is either
multicystic, dysplastic kidneys in a Meckel-like syndrome22
or, as in our study, infantile NPH. A similar genotype–phe-
notype correlation was found in patients with NPHP8
mutations, as hypomorphic mutations were associated with
late-onset NPH (and Joubert syndrome), and loss-of-
function mutations led in most cases to cystic dysplastic
kidneys and Meckel–Gruber syndrome.15
Moreover, most NPHP3 mutations identified in our
cohort map within the tetratricopeptide-repeat motifs.
Interestingly, these motifs have been reported to be over-
represented in ciliary proteins, such as intraflagellar transport
proteins and the proteins mutated in Bardet–Biedl syn-
drome,23 suggesting that these NPHP3 mutations might
affect ciliary function.
Renal phenotype of patients with infantile NPH
Patients with NPHP2 and NPHP3 mutations and also
patients without identified mutations presented with a
similar renal phenotype. The only notable difference was
the faster deterioration of renal function in patients with
NPHP2 mutations compared with patients in the two other
groups, considering that, in all patients with infantile NPH,
the constant features of the renal phenotype were (1) arterial
hypertension, leading to marked medial hypertrophy of the
arterial wall; (2) hyperechogenicity of the kidneys on
ultrasound; and (3) tubular lesions with interstitial fibrosis.
Cysts, found on ultrasound in two of seven patients in the
original description by Gagnadoux et al.5 and in four of nine
patients by Otto et al.,17 were also found in a minority of the
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cases (12/36) in this study. The size of the kidney, reported to
be enlarged in four of seven patients by Gagnadoux et al.,5
was highly variable in our cohort. The characteristic
histological feature of juvenile NPH is the severe and nearly
diffuse tubular atrophy, surrounded by a thick and irregularly
laminated basement membrane.1 Gagnadoux et al.5 reported
on the absence of such anomalies and concluded that
infantile NPH should be considered a distinct entity.
Although the histological abnormalities in most of our
patients are similar to those described by Gagnadoux et al.,5
we also found tubular basement membrane alterations
characteristic of juvenile NPH in a large proportion of
patients in all three patient groups. Thus, the infantile and
juvenile forms of NPH cannot be clearly distinguished on the
basis of localization of the cysts, the size of the kidney, or
renal histology. Screening for mutations should therefore be
directed by age at the onset of ESRD and not by macro- or
microscopic renal morphology.
Extra-renal phenotype of patients with infantile NPH
Extra-renal symptoms are present in approximately 30% of
the cases of juvenile NPH, with retinitis pigmentosa
being the one most frequently reported.12,18 We found
extra-renal symptoms in 80% (36/45) of patients with
early-onset ESRD. Hepatic fibrosis was almost a constant
feature in patients with NPHP3 mutations (6/7), but was
relatively rare in patients with NPHP2 mutations (4/16).
Thus, NPHP3 is an infantile NPH gene associated with
hepatic fibrosis, but as liver disease was also present in
half of the patients without an identified mutation (10/18),
there is apparently further genetic heterogeneity within this
patient group.
Structural cardiac anomalies and situs inversus have rarely
been described in patients with NPH, despite their high
frequency in inv/inv and Nphp3ko/ko mice, which show
laterality problems in 90 and 70% and cardiac defects in 37
and 100%, respectively.22,24 Recently, Bergmann et al.22 found
heart septal or valve defects in three of seven patients with
NPHP3 mutations and situs inversus in one further patient.
In our cohort, heart valve or septal defects were found in nine
patients, although four of them had only mitral insufficiency;
this association may be incidental or the result of hyperten-
sion.25 Nevertheless, severe cardiac defects were found in one
patient with NPHP3 mutations and in three patients with
NPHP2 mutations, two of whom (A8-1, F434-1) also had
situs inversus. One of them (A8-1) was described earlier by
Otto et al.17 The association of cardiac developmental and
laterality defects is well known and can be a consequence of
the dysfunction of the motile cilia, as in the case of primary
ciliary dyskinesia.26
Recurrent lower respiratory disease was found in 10 of 44
patients with infantile NPH. Four of these 10 patients carried
NPHP2 mutations and one carried NPHP3 mutations.
Irregular ciliary motility of the respiratory epithelial cells
has already been described in patients with NPHP1
deletion.27 This irregularity was mild compared with primary
ciliary dyskinesia, and correspondingly only four NPH
patients have been reported in the literature with chronic
sinusitis or bronchitis.27,28 Our findings show that respira-
tory diseases are more frequent in patients with infantile
NPH and implicate inversin and nephrocystin-3 in the
function of motile cilia.
No causative gene has thus far been identified in patients
with NPH and bone abnormalities. Interestingly, we found an
NPHP3 mutation in two patients with cone-shaped epi-
physes. However, the causative role of these mutations is
questionable because they were present in only one of the two
alleles. The development of cone-shaped epiphyses in these
two cases may have been the consequence of mutations
elsewhere. Such oligogenic properties in NPH and associated
disorders have already been described.19,21
Retinitis pigmentosa is the most frequent extra-renal
symptom in juvenile NPH, but it was found in only one
patient with an NPHP3 mutation and not in association with
NPHP2 mutations in this study.
In summary, in our cohort, the characteristic features of
the renal phenotype in infantile NPH were the presence of
hypertension, hyperechogenicity of the kidneys on ultra-
sound, and tubular lesions with interstitial fibrosis. Typical
tubular lesions characteristic of juvenile NPH were also
observed in some patients with infantile NPH. We show that
NPHP3 mutations, known to be associated with
adolescent NPH, can also be found in patients with early-
onset ESRD. These various findings suggest that infantile
and juvenile forms are two different manifestations of the
same disease.
MATERIALS AND METHODS
Patients
A total of 43 unrelated families with infantile NPH were selected
from a worldwide cohort of 380 NPH families, originating mainly
from France and North Africa. Inclusion criteria were age at the
onset of ESRD (5 years, the oldest age reported in a patient with
infantile type NPH17) in association with any of the following
clinical and morphological characteristics of NPH: (1) a history of
polyuria–polydipsia, anemia, or failure to thrive with a progressive
decline in renal function with no or mild proteinuria (o1 g/l); (2)
histological lesions of chronic tubulointerstitial nephritis without
any sign of dysplasia; (3) renal ultrasound findings excluding
congenital malformations of the kidney and the urinary tract; and
(4) family pedigree compatible with autosomal recessive inheritance.
Of the 43 families included, 10 were consanguineous and 4 were
multiplex involving two affected siblings (Tables 1 and 2, Table S1).
Six families with NPHP2 mutations and one family with NPHP3
mutations were published earlier.17,19
Genomic DNA was isolated from peripheral blood by standard
methods, after obtaining informed consent from the patients or
their parents. All experiments were in accordance with the French
ethical committee recommendations and with the Declaration of
Helsinki Principles.
Linkage analysis
Linkage analyses were performed in consanguineous and
multiplex families by genotyping the polymorphic markers
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D9S272, D9S176, D9S1857, and D9S1690, flanking the NPHP2
locus, and D3S1292, D3S1596, D3S1290, and D3S1238 flanking the
NPHP3 locus. Linkage to NPHP2 and to NPHP3 was excluded in
three (F299, F317, F348) and two (F299, F317) families, respectively
(Table S1).
Mutational analysis
Screening for mutations in NPHP2 and NPHP3 was performed in one
affected child in each family, if linkage could not be excluded. NPHP2
was sequenced first. NPHP3 was sequenced subsequently in patients
without NPHP2 mutations on both alleles. Sequence analysis of
NPHP3 was extended to its in-frame transcript FLJ12592 in families
with no or only one mutation detected in NPHP3.
Screening for mutations involved direct sequencing of the coding
exons and the adjacent intronic junctions (primer sequences
available on request). PCR products were treated with Exo-SAP IT
(AP Biotech, Princeton, NJ, USA), sequenced using the dideoxy
chain termination method on a 3130 XL DNA sequencer (Applied
Biosystems, Foster City, CA, USA), and analyzed with the
Sequencher 3.1 program (Genecodes). Amino-acid conservation at
the sites of missense mutations and their possible damaging effects
were assessed using SIFT29 and PolyPhen software.30 Donor and
acceptor sites for splicing were predicted by NetGene2.31 More than
100 control subjects, matched in each case with the patient’s
ethnicity, were tested for the presence of each non-silent nucleotide
variant. Segregation of the identified mutations was investigated in
families with available parental DNA.
Histology
Thirty-nine renal specimens from 31 patients were analyzed by the
same pathologist (MCG). These specimens consisted of 27 renal
biopsies obtained between 6 and 50 months of age and of 12 kidneys
removed at the time of transplantation (after a few months to 6
years on dialysis). Renal biopsies and nephrectomy specimens were
fixed in Dubosq-Brazil or formalin fixative, respectively, then
embedded in paraffin, and serially sectioned and stained with
hematoxylin and eosin, Trichrome light green, periodic acid-Schiff
(PAS), and Jones silver methenamine. Liver biopsy was reviewed in
one patient (patient 1348).
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